Investment Thesis
Serina Therapeutics exhibits critically impaired fundamentals with negative stockholders equity, unsustainable cash burn of $18M annually against only $3.1M cash reserves, and negligible revenue of $130K insufficient to support operations. The company faces imminent solvency risk and will require substantial dilutive financing within months, presenting unacceptable downside risk from a fundamental perspective.
Strengths
- Gross margin of 78.5% demonstrates pricing power on product
- Revenue growth of 132.1% YoY shows positive commercial traction from near-zero base
- Current ratio of 1.71x indicates acceptable short-term liquidity position
Risks
- Negative stockholders equity of -$37K indicates balance sheet insolvency
- Operating cash burn of -$18M annually with only 2-3 months of cash runway remaining
- Revenue of $130K is immaterial and insufficient to cover operating expenses of $24M
- Long-term debt of $11.2M cannot be serviced from operating cash flow
- Extreme operating margin of -18,478% reflects pre-commercial biotech losses
- Imminent capital raise requirement will cause substantial shareholder dilution
Key Metrics to Watch
- Cash runway duration and timing of next financing round
- Operating cash burn rate trajectory and path to breakeven
- Revenue growth sustainability and customer acquisition metrics
- Clinical trial progress, FDA decisions, and pipeline advancement
- Debt covenant compliance and refinancing requirements
Financial Metrics
Revenue
130.0K
Net Income
-19.2M
EPS (Diluted)
$-1.91
Free Cash Flow
-18.0M
Total Assets
7.0M
Cash
3.1M
Profitability Ratios
Gross Margin
78.5%
Operating Margin
-18,478.5%
Net Margin
-14,755.4%
ROE
N/A
ROA
-276.0%
FCF Margin
-13,856.9%
Balance Sheet & Liquidity
Current Ratio
1.71x
Quick Ratio
1.71x
Debt/Equity
N/A
Debt/Assets
100.5%
Interest Coverage
-242.65x
Long-term Debt
11.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T16:54:23.458543 |
Data as of: 2025-12-31 |
Powered by Claude AI